SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...

The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...

VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either aflibercept or ranibizumab in patients with diabetic macular edema, more anterior chamber ...

A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...

Please provide your email address to receive an email when new articles are posted on . Data from the ZIPANGU study showed the use of focal/grid short-pulse laser therapy in patients receiving ...

The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular ...

--Two-Year Data from RISE and RIDE Studies Presented at the American Diabetes Association Annual Scientific Sessions -- SAN DIEGO--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ...

Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated ...